ZA
Zeeshan Ali Tijarat Ali Khan
About Zeeshan Ali Tijarat Ali Khan
Data last updated:
Zeeshan Ali Tijarat Ali Khan is a Director at Fysan Pharmaceuticals Private Limited (since 2016). The company operates in Pharma. Fysan Pharmaceuticals Private Limited reported revenue of ₹3.2 Lakh (FY 2020).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Fysan Pharmaceuticals Private Limited U85300PN2016PTC166869 | Director | 20 Oct 2016 | 2016 | ₹3.2 Lakh (FY 2020) | Active |
Board colleagues of Zeeshan Ali Tijarat Ali Khan
| Name | DIN | Company | Designation |
|---|---|---|---|
| Adil Mahamudmiya Patil | 07633526 | Fysan Pharmaceuticals Private Limited | Director |
| Akshay Ashok Rokade | 07633510 | Fysan Pharmaceuticals Private Limited | Director |
| Mohd Gufran Mohd Shaukat Shaikh | 07633527 | Fysan Pharmaceuticals Private Limited | Director |
| Shoyabkhan Salimkhan Pathan | 07633544 | Fysan Pharmaceuticals Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Zeeshan Ali Tijarat Ali Khan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zeeshan Ali Tijarat Ali Khan
Zeeshan Ali Tijarat Ali Khan currently holds 1 directorship: Fysan Pharmaceuticals Private Limited (Director, since 20 Oct 2016, revenue ₹3.2 Lakh (FY 2020)).
Zeeshan Ali Tijarat Ali Khan was first appointed on 20 Oct 2016 as Director at Fysan Pharmaceuticals Private Limited.
The current boards of Zeeshan Ali Tijarat Ali Khan's companies include Adil Mahamudmiya Patil (Fysan Pharmaceuticals Private Limited), Akshay Ashok Rokade (Fysan Pharmaceuticals Private Limited), Mohd Gufran Mohd Shaukat Shaikh (Fysan Pharmaceuticals Private Limited), Shoyabkhan Salimkhan Pathan (Fysan Pharmaceuticals Private Limited).